International effort to set liver CEUS image-quality standards and a rating tool

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project uses an international Delphi process to identify robust quality indicators for liver CEUS examinations in adults. It aims to translate these indicators into a universal rating scale to improve consistency, reproducibility, and comparability of CEUS imaging in clinical practice and research. The work is conducted in two parts: first, defining quality criteria; second, creating a structured tool to assess image and exam quality. Participation requires substantial ultrasound experience, active CEUS use, and engagement with CEUS education and quality activities. The study is led by the University of Bern and focuses on the SonoVue CEUS agent.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* At least 6 years of active experience in ultrasound diagnostics in internal medicine, radiology, or a related clinical field
* Independent performance of at least 5,000 ultrasound examinations Participation in structured CEUS training
* Performance of at least 800 ultrasound examinations per year in routine clinical practice
* Either: at least 100 independently performed CEUS examinations per year or more than 700 CEUS examinations in total
* Regular participation in ultrasound-related meetings, case reviews, or quality assurance activities within their institution
* Scientific involvement in CEUS, demonstrated by at least one peer-reviewed publication and/or active engagement in CEUS education or training
* Signing the consent form of the participants

Exclusion Criteria:

* Failure to meet the inclusion criteria

Where it's running

• University of Bern
  Bern, Canton of Bern, Switzerland Recruiting

Study contacts

• Study coordinator: Robin Walter, MD
• Email: robin.walter@unibe.ch
• Phone: +41 79 844 71 34

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Low-Dose CBCT AI Model for Interventions

  This trial tests a low-dose CBCT AI model to guide image-guided interventional procedures for adults requiring CBCT during brain, lung, or liver interventions.

  Recruiting at 5 sites Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Hefei, Anhui and 4 other locations · NCT07845929

• Ultrasound in bariatric care to prevent gallstone problems

  This study tests whether preoperative gallbladder ultrasound and related imaging help identify who might benefit from preventive Ursochol after bariatric surgery.

  Recruiting Esbjerg Hospital - University Hospital of Southern Denmark · Esbjerg · NCT07453186

• Pressure-enabled delivery for liver tumors using TriNav: see how it changes tumor-to-normal liver contrast

  This trial tests whether the TriNav infusion system changes how a liver tumor looks on CT compared with normal liver tissue during Y90 treatment in adults with unresectable liver tumors.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT07444645

• Contrast ultrasound imaging of uterine spiral arteries after delivery

  We will try using contrast-enhanced ultrasound after delivery to visualize small uterine spiral arteries and measure uterine artery blood flow in people with a single pregnancy at term who deliver at Máxima Medical Center.

  Recruiting Maxima Medical Center · Veldhoven · NCT07422181

• Using contrast-enhanced ultrasound to predict lymph node spread in small papillary thyroid cancer

  This will test whether contrast-enhanced ultrasound can predict lymph node spread before surgery in people with small (T1N0M0) papillary thyroid cancer.

  Recruiting at 2 sites Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangdong, Guangzhou and 1 other locations · NCT07357571

• Contrast-enhanced ultrasound to track how PRRT works in gastroenteropancreatic neuroendocrine tumors

  This tests whether contrast-enhanced ultrasound can show treatment response to peptide receptor radionuclide therapy (PRRT) in adults with unresectable somatostatin-receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP‑NETs).

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, Rome · NCT07319416

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.